Skip to content
AnalystLens

Intuitive Surgical 8-K Report, Executive Changes (May 15, 2025)

Reports
Leadership Changes·Regulation FD·Exhibits & Filings
Filing Date
Filed May 15, 2025
Period End
May 14, 2025
Security
ISRG
In the record · 2016–202610-K1110-Q338-K100

ISRG filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 100 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jan ’17Jan ’17
  2. Leadership change8-K · May ’22May ’22
  3. Leadership change8-K · Nov ’26Nov ’26

01—Abstract

Summary

Summary of the 8-K filed May 15, 2025. Cited figures are marked; the original filing is the authoritative source.

Intuitive Surgical (ISRG) announced on May 15, 2025 (via Form 8-K) a planned CEO transition effective July 1, 2025.

Board-appointed President David J. Rosa, a 29-year Intuitive veteran who has served as President since May 2023 and as a director since July 2024, will succeed Gary S. Guthart, Ph.D., as Chief Executive Officer.

Guthart, who has led the company for roughly 15 years, will become Executive Chair of the Board and remain an employee in a senior advisory role. Craig H. Barratt, Ph.D., the current Board Chair, will become Lead Independent Director.

The changes reflect the board's succession planning rather than any disclosed performance concern, and the filing contains no reported financial results or guidance changes. For investors, the key economic terms relate to compensation. Rosa's base salary rises from $825,000 to $925,000,a his target bonus increases from 125% to 150% of base salary, and he receives new equity grants of $4 million in RSUs (vesting 25% annually over four years) and $4 million in PSUs (vesting 0-125% of target on February 26, 2028 based on performance).

Guthart's base salary falls from $1,050,000 to $700,000b and he will no longer be eligible for the Corporate Incentive Program bonus going forward, though he will receive a prorated FY2025 bonus for his CEO service. The Company also disclosed no related-person transactions requiring reporting under Item 404(a).

From a strategic standpoint, the transition is orderly and planned: the outgoing CEO remains involved as Executive Chair, and the incoming CEO has deep, long-standing operational and strategic experience, including founding the clinical engineering and endoluminal groups that led to the da Vinci SP and Ion systems. Investors will likely focus on whether continuity of strategy and product execution holds through the handover and on how the new leadership approaches growth, global expansion, and the Quintuple Aim priorities.

02—Key points

Key Highlights

  1. Board appointed President David J. Rosa (age 57) as CEO effective July 1, 2025, succeeding Gary Guthart, Ph.D., who has served as CEO for about 15 years.
  2. Guthart becomes Executive Chair of the Board and remains with the company in a senior advisory capacity and as a director.
  3. Craig H. Barratt, Ph.D., current Board Chair, becomes Lead Independent Director effective July 1, 2025.
  4. Rosa's base salary increases from $825,000 to $925,000, and his target bonus rises from 125% to 150% of base salary for FY2025.
  5. Rosa receives new equity awards of $4.0 million in RSUs (25% annual vesting over four years) and $4.0 million in PSUs (0-125% of target, vesting February 26, 2028).
  6. Guthart's base salary decreases from $1,050,000 to $700,000, and he is no longer eligible for the Corporate Incentive Program bonus going forward, though he receives a prorated FY2025 bonus.
  7. Rosa has a 29-year tenure at Intuitive, having led the development of the da Vinci SP and Ion systems, and currently serves on the board of Kardium Inc.

03—Questions

Frequently Asked Questions

  1. Who will lead Intuitive Surgical after July 1, 2025?

    David J. Rosa, currently President, will become Chief Executive Officer effective July 1, 2025, replacing Gary S. Guthart, Ph.D., who has served as CEO for roughly 15 years.

  2. What is Gary Guthart's role after the transition?

    Guthart will become Executive Chair of the Board, continue as a director, and remain an employee in a senior advisory capacity. His base salary is reduced to $700,000 and he will no longer be eligible for the annual corporate bonus program going forward, though he will receive a prorated FY2025 bonus for his CEO service.

  3. How is Rosa being compensated as CEO?

    Rosa's base salary increases to $925,000 from $825,000, and his target bonus opportunity rises to 150% of base salary from 125%. He also receives $4.0 million in RSUs vesting 25% annually over four years and $4.0 million in PSUs that can vest from 0-125% of target on February 26, 2028, subject to performance and continued service.

  4. Why is the leadership change happening, and does it signal any company problems?

    The company describes the transition as the result of the Board's planned succession process. The filing and press release do not cite any financial or operational problems, and they state that Guthart will support a smooth handover.

  5. What does this change mean for Intuitive's strategy and product pipeline?

    Rosa has been instrumental in shaping the company's strategy, product pipeline, and global expansion, including founding the clinical engineering and endoluminal groups behind the da Vinci SP and Ion systems. The press release emphasizes continuity around the Quintuple Aim of improving outcomes, care team experience, access, and lowering total cost to treat. The filing itself provides no new financial guidance.

04—Continue

← View all 8-K filings